Price
$82.98+9.24%Social Signal Score
Analyst Ratings
12 analystsRevenue
$2.21B+7.34%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Bryan C. Hanson
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 20,584
- Beta
- 0.69
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.20
Financials
Revenue
$2.21B+7.3%Net Income
$92.00M-73.8%EBITDA
$172.00M-70.6%Free Cash Flow
$144.00M-53.9%EPS (diluted)
$0.53-73.9%Shares Outstanding (diluted)
174.40M+1.1%Operating Expenses
$1.10BCash & Debt
$403.00MReturn of Capital
$288.00MRevenue by Segment (annual)
$6.35BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $8.32B | $1.56B | $8.94 |
| 2024 | $8.25B | $479.00M | $2.77 |
| 2023 | $8.20B | $1.35B | $7.79 |
| 2022 | $8.13B | $1.34B | $7.79 |
| 2021 | $8.17B | $1.46B | $8.47 |
| 2020 | $7.28B | $1.14B | $6.60 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from SOLV's reported EPS growth of 6.3% a year over 5 years.
- EPS in 5 years
- $12.13
- Implied price
- $109.17
- Return from $87.85
- 4.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $54.28 — -38.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 5 | 7 | 9 | 11 | 13 |
|---|---|---|---|---|---|
| -3.7% | -15.9% | -10.0% | -5.4% | -1.5% | 1.8% |
| 1.3% | -11.5% | -5.3% | -0.5% | 3.6% | 7.1% |
| 6.3% | -7.1% | -0.7% | 4.4% | 8.7% | 12.4% |
| 11.3% | -2.8% | 4.0% | 9.4% | 13.8% | 17.7% |
| 16.3% | 1.6% | 8.7% | 14.3% | 18.9% | 23.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (16)
- Newsseekingalpha.com·18d ago·Negative
Solventum: Divestiture Unlocking Upside In A Spinoff Revaluation Play Solventum trades at a significant discount to medical technology peers, with a forward P/E of ~13x and suppressed EV/EBITDA multiples. Management is executing a portfolio optimization, including a potential spin-off of the Health Information Systems segment to unlock value and reduce debt. Raised 2026 EPS guidance to $7.10-$7.20 and operating margins to 22.2%-22.7%, signaling margin expansion and improved free cash flow alloca…
View source ↗ - Newszacks.com·18d ago·Positive
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now SOLV's strong Q2 performance, growth investments and cost-saving program support its outlook, though higher raw material costs remain a concern.
View source ↗ - Newszacks.com·20d ago·Positive
Why Solventum (SOLV) is a Top Stock for the Long-Term Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Solventum Corporation (SOLV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Solventum Corporation (SOLV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·31d ago·Neutral
SOLV Energy: PV Enabler Looks A Lot Brighter Here
View source ↗ - Newsprnewswire.com·33d ago·Neutral
Solventum to Participate in the 2026 Wells Fargo Healthcare Conference EAGAN, Minn., Sept. 2, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, Sept.
View source ↗ - Newszacks.com·33d ago·Positive
Should Investors Buy SOLV as Growth Improves but Debt Risks Persist? Solventum's growth, higher earnings outlook and cost cuts strengthen its case, but heavy debt and 2027 margin risks temper the upside.
View source ↗ - Newszacks.com·33d ago·Positive
Earnings Growth & Price Strength Make Solventum (SOLV) a Stock to Watch Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
View source ↗ - News (RSS)investing·42d ago·Neutral
Solventum Corp stock hits 52-week high at 90.05 USD
View source ↗ - News (RSS)fool·46d ago·Positive
SOLV Energy (MWH) Q2 2026 Earnings Call Transcript $8.9B backlog provides visibility through 2028 as solar and storage demand surges.
View source ↗ - Newszacks.com·49d ago·Positive
Why Solventum (SOLV) is a Top Value Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·52d ago·Neutral
SOLV Plans Health Information Systems Business Spinoff to Drive Growth Solventum plans to spin off its $1.4B HIS business, sharpening its MedTech focus while giving HIS more flexibility to pursue growth.
View source ↗ - Newsmarketbeat.com·53d ago·Neutral
SOLV Energy Q2 Earnings Call Highlights SOLV Energy NASDAQ: MWH reported record first-half results for 2026, citing increased new-construction activity, project execution and contributions from prior acquisitions. The company also raised its full-year revenue and adjusted EBITDA outlook while reporting a 44% year-over-year increase in backlog.
View source ↗ - Newsglobenewswire.com·54d ago·Negative
SOLV Energy Reports Second Quarter 2026 Financial Results SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- SOLV Energy, Inc. (“SOLV” or the “Company”) (Nasdaq: MWH), a leading provider of infrastructure services to the power industry, today announced financial results for the second quarter ended June 30, 2026. Financial Summary (in $ millions except percentages) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Revenue 951 536 1,628 944 Gross Profit 1 140 113 259 1…
View source ↗ - Newszacks.com·56d ago·Positive
Here's Why Solventum (SOLV) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsmarketbeat.com·58d ago·Neutral
Solventum Q2 Earnings Call Highlights Solventum NYSE: SOLV reported second-quarter results that exceeded its internal expectations, supported by broad-based segment performance, planned order activity ahead of an ERP cutover and a tariff refund benefit. The company also announced plans to separate its Health Information Systems, or HIS, business as part of a broader effort to sharpen its focus on medical technology markets.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $1.35 per share
Typical surprise +9.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$2.55 vs $1.90beat
- Tue, May 5$1.48 vs $1.35beat
- Thu, Feb 26$1.57 vs $1.50beat
- Thu, Nov 6$1.50 vs $1.43beat
- Thu, Aug 7$1.69 vs $1.45beat
- Thu, May 8$1.34 vs $1.21beat
Estimates and results for SOLV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SOLV officers and directors.
- Bought
- $100k
- Sold
- —
1 trade
0 trades
- Wendell Amy Mcbridebought
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 11, 2026 (41d later)Buy$1,001 - $15,000
- French Hillhouse · AR02 · disclosed Jan 23, 2026 (23d later)Sell$15,001 - $50,000
- Ronald Lee Wydensenate · OR · disclosed Feb 21, 2025 (15d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Feb 12, 2025 (28d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Jun 14, 2024 (42d later)Buy$1,001 - $15,000
- Gary C. Peterssenate · MI · disclosed May 23, 2024 (9d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.